BCHT(SH:688276) Zheng Quan Shi Bao Wang·2026-01-16 08:19Core Viewpoint - The company expects a net profit loss attributable to shareholders of 220 million to 280 million yuan for the fiscal year 2025, marking a shift from profit to loss year-on-year [1] Group 1: Financial Performance - The projected net profit loss for 2025 is between 220 million to 280 million yuan, indicating a significant decline compared to previous years [1] - The company is experiencing a downturn in sales revenue from its herpes zoster live attenuated vaccine, primarily due to factors such as the public's awareness of the disease and willingness to receive the vaccine [1] Group 2: Market Challenges - There has been a return of confirmed revenue for the herpes zoster vaccine due to expiration before administration, impacting overall sales [1] - The company is facing reduced sales of its varicella live attenuated vaccine, attributed to a decline in newborn birth rates and increased market competition [1] Group 3: Strategic Initiatives - To enhance public awareness of herpes zoster prevention and fulfill corporate social responsibility, the company is actively promoting welfare projects and adjusting prices to improve vaccine uptake [1] - The unit price of the herpes zoster vaccine has decreased as part of the company's strategy to boost vaccination rates [1]